by Gabrielle Morrow | Apr 30, 2015 | Press Release | 0 Comments
NEW YORK, N.Y. – April 30, 2015 – CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class modulator of the brain’s innate immune system, as a potential treatment for Alzheimer’s disease (AD), announced today it has appointed Sophie Egholm... read more
by Daniel Gray | Sep 30, 2014 | Press Release | 0 Comments
New York, NY – September 30, 2014 – CereSpir™ Incorporated, a company developing CSP-1103, a first-in-class microglial modulator, as a potential treatment for Alzheimer’s disease (AD), announced today it has appointed former pharmaceutical senior executive Adrian... read more
by Daniel Gray | Feb 21, 2014 | Press Release | 0 Comments
The Advisory Board includes internationally recognized clinicians and researchers in Alzheimer’s disease. February 21, 2014 – New York, NY– CereSpir™ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for... read more
by Daniel Gray | Jan 10, 2014 | Press Release | 0 Comments
January 9, 2014 – New York, NY– CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator as a potential treatment for Alzheimer’s disease, today announced Chris Griffett, BSc (Hons), C.Biol., FTOPRA, will serve as the Company’s Vice... read more
by Daniel Gray | Nov 26, 2013 | Press Release | 0 Comments
New York, NY – November 26, 2013 – CereSpir™ Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer’s disease, announced today Richard Margolin, MD, has joined the Company as Vice President, Clinical... read more
